Literature DB >> 18251700

JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.

Fumiyo Ikeda1, Takuma Matsubara, Taro Tsurukai, Kenji Hata, Riko Nishimura, Toshiyuki Yoneda.   

Abstract

INTRODUCTION: RANKL is known to be important not only for differentiation and activation of osteoclasts but also for their survival. Experimentally, apoptosis of osteoclasts is rapidly induced by the deprivation of RANKL. RANKL activates Elk-related tyrosine kinase (ERK), p38, c-Jun N-terminal kinase (JNK), and NF-kappaB pathways through TRAF6 in osteoclasts and the precursor cells. It has been shown that ERK is critical for regulation of osteoclast survival. However, an involvement of other RANKL signaling pathways such as JNK signaling in survival of osteoclasts has not been fully understood yet.
MATERIALS AND METHODS: Osteoclasts derived from primary mouse bone marrow cells by soluble RANKL (sRANKL) were treated with a JNK inhibitor, SP600125, or infected with adenovirus carrying dominant-negative (DN)-c-jun, DN-c-fos, mitogen-activated protein kinase kinase 1 (MEKK1), I-kappaBalpha mutant, or NF-kappaB components, p50 and p65. Osteoclasts were cultured with or without sRANKL, and apoptotic phenotype was determined by TUNEL assay, DAPI staining, and expression of cleaved caspase 3 followed by TRACP staining.
RESULTS: Overexpression of TRAF6 activated JNK and NF-kappaB signaling pathways and clearly prevented osteoclasts from apoptosis caused by abrogation of sRANKL. An anti-apoptotic effect of RANKL/RANK/TRAF6 signaling on osteoclast was inhibited by JNK-specific inhibitor SP600125 and by overexpression of dominant-negative JNK1, c-jun, and c-fos. Also, overexpression of MEKK1 inhibited apoptosis of osteoclasts even in the absence of sRANKL along with activation of JNK/c-jun signaling. On the other hand, blockade of NF-kappaB signaling by I-kappaBalpha mutant or overexpression of NF-kappaB components showed a marginal effect on apoptosis of osteoclasts.
CONCLUSIONS: An important role of RANKL-induced activation of MEKK1/JNK/c-jun signaling in the regulation of apoptosis in osteoclasts was shown. Our study suggests that c-fos plays a role as a partner of activator protein-1 factor, c-jun, during the regulation of apoptosis in osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18251700     DOI: 10.1359/jbmr.080211

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  48 in total

1.  Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling.

Authors:  W He; B N Cronstein
Journal:  Purinergic Signal       Date:  2012-02-05       Impact factor: 3.765

2.  Effects of orthodontic force magnitude on cell apoptosis and RANKL-induced osteoclastogenesis : Studies in a rat model.

Authors:  S Kaya; M Çifter; A Çekici; V Olgaç; H İşsever; G Işık
Journal:  J Orofac Orthop       Date:  2020-01-10       Impact factor: 1.938

3.  A new regulator of osteoclastogenesis: estrogen response element-binding protein in bone.

Authors:  Hong Chen; Linda C Gilbert; X Lu; Zhaofan Liu; Shaojin You; M Neale Weitzmann; Mark S Nanes; John Adams
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

Review 4.  Regulation of osteoclast-mediated bone resorption by microRNA.

Authors:  Ling Ji; Xinyi Li; Shushu He; Song Chen
Journal:  Cell Mol Life Sci       Date:  2022-05-10       Impact factor: 9.261

5.  Hydrogen sulfide epigenetically mitigates bone loss through OPG/RANKL regulation during hyperhomocysteinemia in mice.

Authors:  Jyotirmaya Behera; Akash K George; Michael J Voor; Suresh C Tyagi; Neetu Tyagi
Journal:  Bone       Date:  2018-06-13       Impact factor: 4.398

6.  S100A9 promotes human lung fibroblast cells activation through receptor for advanced glycation end-product-mediated extracellular-regulated kinase 1/2, mitogen-activated protein-kinase and nuclear factor-κB-dependent pathways.

Authors:  X Xu; H Chen; X Zhu; Y Ma; Q Liu; Y Xue; H Chu; W Wu; J Wang; H Zou
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

7.  6-Shogaol promotes bone resorption and accelerates orthodontic tooth movement through the JNK-NFATc1 signaling axis.

Authors:  Xiaofang Zhu; Hao Yuan; Ouyang Ningjuan; Carroll Ann Trotman; Thomas E Van Dyke; Jake Jinkun Chen; Guofang Shen
Journal:  J Bone Miner Metab       Date:  2021-06-30       Impact factor: 2.626

8.  Chemical biology investigation of cell death pathways activated by endoplasmic reticulum stress reveals cytoprotective modulators of ASK1.

Authors:  InKi Kim; Chih-Wen Shu; Wenjie Xu; Chung-Wai Shiau; Daniel Grant; Stefan Vasile; Nicholas D P Cosford; John C Reed
Journal:  J Biol Chem       Date:  2008-11-12       Impact factor: 5.157

9.  RANKL-mediated osteoclastogenic differentiation of macrophages in the abdominal aorta of angiotensin II-infused apolipoprotein E knockout mice.

Authors:  Teruyoshi Tanaka; Matthew Kelly; Yuichiro Takei; Dai Yamanouchi
Journal:  J Vasc Surg       Date:  2018-04-21       Impact factor: 4.268

10.  A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.

Authors:  Guoju Hong; Zhenqiu Chen; Xiaorui Han; Lin Zhou; Fengxiang Pang; Rishana Wu; Yingshan Shen; Xiaoming He; Zhinan Hong; Ziqi Li; Wei He; Qiushi Wei
Journal:  Clin Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.